The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials

Angiotensin-converting enzyme 2 (ACE2) is the receptor for COVID-19 (SARs-CoV-2). ACE2 protects the lung and heart from acute respiratory distress syndrome (ARDS) and acute myocarditis and arrhythmias, because it breaks down Angiotensin II, which has inflammatory effects in the lung and heart as wel...

Descripción completa

Detalles Bibliográficos
Autores principales: Lumbers, Eugenie R., Delforce, Sarah J., Pringle, Kirsty G., Smith, Gary R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256451/
https://www.ncbi.nlm.nih.gov/pubmed/32574336
http://dx.doi.org/10.3389/fmed.2020.00248
_version_ 1783539911647821824
author Lumbers, Eugenie R.
Delforce, Sarah J.
Pringle, Kirsty G.
Smith, Gary R.
author_facet Lumbers, Eugenie R.
Delforce, Sarah J.
Pringle, Kirsty G.
Smith, Gary R.
author_sort Lumbers, Eugenie R.
collection PubMed
description Angiotensin-converting enzyme 2 (ACE2) is the receptor for COVID-19 (SARs-CoV-2). ACE2 protects the lung and heart from acute respiratory distress syndrome (ARDS) and acute myocarditis and arrhythmias, because it breaks down Angiotensin II, which has inflammatory effects in the lung and heart as well as in the kidney. When SARS-CoV-2 binds to ACE2, it suppresses it, so this protective action of ACE2 is lost. Death from COVID-19 is due to ARDS and also heart failure and acute cardiac injury. Drugs that prevent the inflammatory actions of Angiotensin II (i.e., Angiotensin receptor blockers, ARBs) prevent acute lung injury caused by SARS-CoV. Clinical trials are underway to test the risks and benefits of ARBs and angiotensin-converting enzyme inhibitors (ACEIs) in COVID-19 patients requiring hospitalization. Other potential treatments are also discussed.
format Online
Article
Text
id pubmed-7256451
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72564512020-06-10 The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials Lumbers, Eugenie R. Delforce, Sarah J. Pringle, Kirsty G. Smith, Gary R. Front Med (Lausanne) Medicine Angiotensin-converting enzyme 2 (ACE2) is the receptor for COVID-19 (SARs-CoV-2). ACE2 protects the lung and heart from acute respiratory distress syndrome (ARDS) and acute myocarditis and arrhythmias, because it breaks down Angiotensin II, which has inflammatory effects in the lung and heart as well as in the kidney. When SARS-CoV-2 binds to ACE2, it suppresses it, so this protective action of ACE2 is lost. Death from COVID-19 is due to ARDS and also heart failure and acute cardiac injury. Drugs that prevent the inflammatory actions of Angiotensin II (i.e., Angiotensin receptor blockers, ARBs) prevent acute lung injury caused by SARS-CoV. Clinical trials are underway to test the risks and benefits of ARBs and angiotensin-converting enzyme inhibitors (ACEIs) in COVID-19 patients requiring hospitalization. Other potential treatments are also discussed. Frontiers Media S.A. 2020-05-22 /pmc/articles/PMC7256451/ /pubmed/32574336 http://dx.doi.org/10.3389/fmed.2020.00248 Text en Copyright © 2020 Lumbers, Delforce, Pringle and Smith. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Lumbers, Eugenie R.
Delforce, Sarah J.
Pringle, Kirsty G.
Smith, Gary R.
The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials
title The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials
title_full The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials
title_fullStr The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials
title_full_unstemmed The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials
title_short The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials
title_sort lung, the heart, the novel coronavirus, and the renin-angiotensin system; the need for clinical trials
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256451/
https://www.ncbi.nlm.nih.gov/pubmed/32574336
http://dx.doi.org/10.3389/fmed.2020.00248
work_keys_str_mv AT lumberseugenier thelungtheheartthenovelcoronavirusandthereninangiotensinsystemtheneedforclinicaltrials
AT delforcesarahj thelungtheheartthenovelcoronavirusandthereninangiotensinsystemtheneedforclinicaltrials
AT pringlekirstyg thelungtheheartthenovelcoronavirusandthereninangiotensinsystemtheneedforclinicaltrials
AT smithgaryr thelungtheheartthenovelcoronavirusandthereninangiotensinsystemtheneedforclinicaltrials
AT lumberseugenier lungtheheartthenovelcoronavirusandthereninangiotensinsystemtheneedforclinicaltrials
AT delforcesarahj lungtheheartthenovelcoronavirusandthereninangiotensinsystemtheneedforclinicaltrials
AT pringlekirstyg lungtheheartthenovelcoronavirusandthereninangiotensinsystemtheneedforclinicaltrials
AT smithgaryr lungtheheartthenovelcoronavirusandthereninangiotensinsystemtheneedforclinicaltrials

Ejemplares similares